661 related articles for article (PubMed ID: 20616599)
1. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
2. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Lee JM; Han KH
Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
4. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
8. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
9. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Peck-Radosavljevic M; Greten TF; Lammer J; Rosmorduc O; Sangro B; Santoro A; Bolondi L
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
11. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Lencioni R; Chen XP; Dagher L; Venook AP
Oncologist; 2010; 15 Suppl 4():42-52. PubMed ID: 21115580
[TBL] [Abstract][Full Text] [Related]
13. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
14. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
16. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
17. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
19. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
